Publications by authors named "Scott M Dehm"

73Publications

Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary.

Urology 2020 Dec 26. Epub 2020 Dec 26.

Genitourinary Malignancies Research Center, Cleveland Clinic, Cleveland, OH; Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. Electronic address:

View Article and Find Full Text PDF
December 2020

Triple Aberrant Prostate Cancer (TAPC) - Aggregate role of aberrations in , and on ETS gene fusions and prognosis in metastatic castrate resistant prostate cancer.

Am J Clin Exp Urol 2020 15;8(4):106-115. Epub 2020 Aug 15.

Division of Hematology, Oncology & Transplantation, Department of Medicine, University of Minnesota Minneapolis, USA.

View Article and Find Full Text PDF
August 2020

Androgen receptor: Functional roles and facets of regulation in urology.

Asian J Urol 2020 Jul 19;7(3):189-190. Epub 2020 May 19.

Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.

View Article and Find Full Text PDF
July 2020

Androgen receptor variants: RNA-based mechanisms and therapeutic targets.

Hum Mol Genet 2020 Sep;29(R1):R19-R26

Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.

View Article and Find Full Text PDF
September 2020

Androgen Receptor Dependence.

Adv Exp Med Biol 2019 ;1210:333-350

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.

View Article and Find Full Text PDF
February 2020

Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer.

Clin Cancer Res 2020 03 15;26(5):1054-1064. Epub 2019 Nov 15.

Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota.

View Article and Find Full Text PDF
March 2020

PEG10 Promoter-Driven Expression of Reporter Genes Enables Molecular Imaging of Lethal Prostate Cancer.

Cancer Res 2019 11 17;79(21):5668-5680. Epub 2019 Sep 17.

Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota.

View Article and Find Full Text PDF
November 2019

A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities.

Nucleic Acids Res 2019 06;47(11):5634-5647

Northern Institute for Cancer Research, Newcastle University, Paul O'Gorman Building, Framlington Place, Newcastle Upon Tyne, NE2 4HH, UK.

View Article and Find Full Text PDF
June 2019

AR-Variant-Positive CTC: A Surrogate for a Surrogate for Taxane Therapy Outcome?

Clin Cancer Res 2019 03 27;25(6):1696-1698. Epub 2018 Dec 27.

Department of Medicine, University of Washington School of Medicine, Seattle, Washington.

View Article and Find Full Text PDF
March 2019

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.

Eur Urol 2018 11 23;74(5):562-572. Epub 2018 Jul 23.

Monash Partners Comprehensive Cancer Consortium, Monash Biomedicine Discovery Institute Cancer Program, Prostate Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Clayton, VIC, Australia; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Melbourne Urological Research Alliance (MURAL), Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC, Australia. Electronic address:

View Article and Find Full Text PDF
November 2018

Inhibition of androgen receptor transactivation function by adenovirus type 12 E1A undermines prostate cancer cell survival.

Prostate 2018 11 15;78(15):1140-1156. Epub 2018 Jul 15.

Department of Anatomy and Cell Biology, UF Health Cancer Center and UF Genetics Institute, University of Florida College of Medicine, Gainesville, Florida.

View Article and Find Full Text PDF
November 2018

Indel detection from DNA and RNA sequencing data with transIndel.

BMC Genomics 2018 Apr 19;19(1):270. Epub 2018 Apr 19.

Masonic Cancer Center, University of Minnesota, 420 Delaware St SE, Minneapolis, MN, 55455, USA.

View Article and Find Full Text PDF
April 2018

Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.

Endocrinology 2017 06;158(6):1533-1542

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455.

View Article and Find Full Text PDF
June 2017

Methods for Identifying and Quantifying mRNA Expression of Androgen Receptor Splicing Variants in Prostate Cancer.

Methods Mol Biol 2016 ;1443:165-77

Masonic Cancer Center and Department of Laboratory Medicine and Pathology, University of Minnesota Twin Cities, Mayo Mail Code 806, 420 Delaware Street SE, Minneapolis, MN, USA.

View Article and Find Full Text PDF
November 2017

Lessons from tissue compartment-specific analysis of androgen receptor alterations in prostate cancer.

J Steroid Biochem Mol Biol 2017 02 28;166:28-37. Epub 2016 Apr 28.

Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA; Department of Urology, University of Minnesota, Minneapolis, MN, USA. Electronic address:

View Article and Find Full Text PDF
February 2017

Clonal origin and spread of metastatic prostate cancer.

Endocr Relat Cancer 2016 Apr 21;23(4):R207-17. Epub 2016 Mar 21.

Masonic Cancer CenterUniversity of Minnesota, Minneapolis, MN, USA Department of Laboratory Medicine and PathologyUniversity of Minnesota, Minneapolis, MN, USA Department of UrologyUniversity of Minnesota, Minneapolis, MN, USA

View Article and Find Full Text PDF
April 2016

Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target.

J Natl Cancer Inst 2016 May 11;108(5). Epub 2015 Dec 11.

Affiliations of authors:Cancer Research UK Cambridge Institute, University of Cambridge , Cambridge, UK (MA, CEM, NP, HIZ, AQ, AB, SM, BM, CE, SL, SW, VRZ, GS, RR, HM, AGL, CD, CT, AL, RS, JY, RS, JSC, JRG, ST, DEN); School of Medical Sciences, University of Aberdeen , Aberdeen, UK (FO, IJM); Department of Pathology, Addenbrooke's Hospital , Cambridge, UK (AYW, NS); Institute of Human Genetics, Jena University Hospital , Jena , Germany (ME, KL, WH, AB); Dame Roma Mitchell Cancer Research Laboratories, School of Medicine, Faculty of Health Sciences, University of Adelaide , Australia (LAS, WDT); Freemasons Foundation Centre for Men's Health, School of Medicine, Faculty of Health Sciences, University of Adelaide , Australia (LAS, WDT); Diatherix , Huntsville, AL (EG); Masonic Cancer Center, University of Minnesota , Minneapolis, MN (SMD); The Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia , Vancouver BC , Canada (PSR); Centre for Molecular Medicine Norway, Nordic EMBL Partnership, University of Oslo and Oslo University Hospital , Oslo , Norway (IGM); Department of Cancer Prevention, Institute of Cancer Research and Department of Urology, Oslo University Hospital , Oslo , Norway (IGM); Prostate Cancer UK/Movember Centre of Excellence, Queens University , Belfast , UK (IGM); Department of Oncology, Addenbrooke's Hospital , Cambridge, UK (MA, DEN).

View Article and Find Full Text PDF
May 2016

Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies.

Nucleic Acids Res 2015 Jul 23;43(12):5880-97. Epub 2015 Apr 23.

Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55905, USA Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55905, USA

View Article and Find Full Text PDF
July 2015

Constitutive activity of the androgen receptor.

Adv Pharmacol 2014 ;70:327-66

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA. Electronic address:

View Article and Find Full Text PDF
January 2015

Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.

Endocr Relat Cancer 2014 Aug 23;21(4):T87-T103. Epub 2014 May 23.

Departments of Molecular Genetics and MedicineDuke University, 213 Research Dr, 0045 CARL Building, Durham, North Carolina 27710, USADepartment of MedicineDuke Cancer Institute, Duke University, Durham, North Carolina, USAMasonic Cancer CenterUniversity of Minnesota Masonic Cancer Center, Mayo Mail Code 806, 420 Delaware Street SE, Minneapolis, Minnesota 55455, USADepartment of Laboratory Medicine and PathologyUniversity of Minnesota, Minneapolis, Minnesota, USADepartments of Molecular Genetics and MedicineDuke University, 213 Research Dr, 0045 CARL Building, Durham, North Carolina 27710, USADepartment of MedicineDuke Cancer Institute, Duke University, Durham, North Carolina, USAMasonic Cancer CenterUniversity of Minnesota Masonic Cancer Center, Mayo Mail Code 806, 420 Delaware Street SE, Minneapolis, Minnesota 55455, USADepartment of Laboratory Medicine and PathologyUniversity of Minnesota, Minneapolis, Minnesota, USA

View Article and Find Full Text PDF
August 2014

SHEAR: sample heterogeneity estimation and assembly by reference.

BMC Genomics 2014 Jan 29;15:84. Epub 2014 Jan 29.

Quantitative Biomedical Research Center, University of Texas Southwestern Medical Center, Dallas, TX, USA.

View Article and Find Full Text PDF
January 2014

TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.

Proc Natl Acad Sci U S A 2013 Oct 7;110(43):17492-7. Epub 2013 Oct 7.

Masonic Cancer Center, Graduate Program in Molecular, Cellular, and Developmental Biology and Genetics, and Biostatistics and Bioinformatics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455.

View Article and Find Full Text PDF
October 2013

Test-firing ammunition for spliceosome inhibition in cancer.

Authors:
Scott M Dehm

Clin Cancer Res 2013 Nov 4;19(22):6064-6. Epub 2013 Oct 4.

Author's Affiliation: Masonic Cancer Center and Department of Laboratory Medicine and Pathology, University of Minnesota, Twin Cities.

View Article and Find Full Text PDF
November 2013

mRNA splicing variants: exploiting modularity to outwit cancer therapy.

Authors:
Scott M Dehm

Cancer Res 2013 Sep 22;73(17):5309-14. Epub 2013 Aug 22.

Department of Laboratory Medicine and Pathology, Masonic Cancer Center, University of Minnesota Twin Cities, Minneapolis, MN 55455, USA.

View Article and Find Full Text PDF
September 2013

Androgen receptor gene rearrangements: new perspectives on prostate cancer progression.

Curr Drug Targets 2013 Apr;14(4):441-9

Graduate Program in Microbiology, Immunology, and Cancer Biology, University of Minnesota, Minneapolis, MN 55455, USA.

View Article and Find Full Text PDF
April 2013

FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants.

Prostate 2013 Jul 6;73(10):1017-27. Epub 2013 Feb 6.

Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.

View Article and Find Full Text PDF
July 2013

Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression.

Horm Cancer 2013 Apr 10;4(2):61-9. Epub 2013 Jan 10.

Masonic Cancer Center, University of Minnesota, Twin Cities, Minneapolis, MN 55455, USA.

View Article and Find Full Text PDF
April 2013

Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.

Cancer Res 2013 Jan 1;73(2):483-9. Epub 2012 Nov 1.

Masonic Cancer Center, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA.

View Article and Find Full Text PDF
January 2013

Biomarker-based targeting of the androgen-androgen receptor axis in advanced prostate cancer.

Adv Urol 2012 22;2012:781459. Epub 2012 Aug 22.

Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

View Article and Find Full Text PDF
September 2012

Alternatively spliced androgen receptor variants.

Endocr Relat Cancer 2011 Oct 20;18(5):R183-96. Epub 2011 Sep 20.

Department of Laboratory Medicine and Pathology, Masonic Cancer Center, University of Minnesota, Mayo Mail Code 806, 420 Delaware Street SE, Minneapolis, Minnesota 55455, USA.

View Article and Find Full Text PDF
October 2011

Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.

Cancer Res 2011 Mar 19;71(6):2108-17. Epub 2011 Jan 19.

Department of Electrical and Computer Engineering, Masonic Cancer Center, University of Minnesota, Twin Cities, Minnesota 55455, USA.

View Article and Find Full Text PDF
March 2011

Induction of prostatic intraepithelial neoplasia and modulation of androgen receptor by ETS variant 1/ETS-related protein 81.

Cancer Res 2009 Oct 29;69(20):8102-10. Epub 2009 Sep 29.

Department of Cell Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.

View Article and Find Full Text PDF
October 2009

Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis.

Prostate 2008 Nov;68(15):1696-706

Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.

View Article and Find Full Text PDF
November 2008

Androgen receptor structural and functional elements: role and regulation in prostate cancer.

Mol Endocrinol 2007 Dec 17;21(12):2855-63. Epub 2007 Jul 17.

Departments of Urology and Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, 200 First Street Southwest, Rochester, Minnesota 55905, USA.

View Article and Find Full Text PDF
December 2007

Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells.

J Biol Chem 2006 Sep 25;281(38):27882-93. Epub 2006 Jul 25.

Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.

View Article and Find Full Text PDF
September 2006

The modification of Sp3 isoforms by SUMOylation has differential effects on the SRC1A promoter.

Gene 2006 Sep 5;379:68-78. Epub 2006 May 5.

Cancer Research Unit, Health Research Division, Saskatchewan Cancer Agency, Saskatoon, SK, Canada.

View Article and Find Full Text PDF
September 2006

Molecular regulation of androgen action in prostate cancer.

J Cell Biochem 2006 Oct;99(2):333-44

Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.

View Article and Find Full Text PDF
October 2006

Regulation of androgen receptor signaling in prostate cancer.

Expert Rev Anticancer Ther 2005 Feb;5(1):63-74

Mayo Clinic College of Medicine, 200 First Street, SW, Rochester, MN 55905, USA.

View Article and Find Full Text PDF
February 2005

Regulation of alternative SRC promoter usage in HepG2 hepatocellular carcinoma cells.

Gene 2004 Aug;337:141-50

Cancer Research Unit, Health Research Division, Saskatchewan Cancer Agency, Saskatoon, Canada.

View Article and Find Full Text PDF
August 2004

SRC gene expression in human cancer: the role of transcriptional activation.

Biochem Cell Biol 2004 Apr;82(2):263-74

Department of Biochemistry, University of Saskatchewan, Saskatoon, Canada.

View Article and Find Full Text PDF
April 2004

SRC proximal and core promoter elements dictate TAF1 dependence and transcriptional repression by histone deacetylase inhibitors.

Mol Cell Biol 2004 Mar;24(6):2296-307

Department of Biochemistry, University of Saskatchewan, Saskatoon, Saskatchewan S7N 5E5, Canada.

View Article and Find Full Text PDF
March 2004

The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases.

Oncogene 2002 Sep;21(41):6340-7

Department of Biochemistry, University of Saskatchewan, Saskatoon SK, Canada S7N 5E5.

View Article and Find Full Text PDF
September 2002